

**SDC Table 1 Associations of moderate PTD (MPTD) and very PTD (VPTD) with NNRTI-, LPV/r- and other PI-based regimens**

			MPTD (34-36 gestational weeks)		VPTD (<34 gestational weeks)	
		N	%MPTD	aOR <sup>a</sup> (95%CI)	%VPTD	aOR <sup>b</sup> (95%CI)
Regimen in pregnancy	NNRTI+2NRTI	6073	6.6		3.75	
	LPV/r+2NRTI	1889	5.2	1.00	3.8	1.00
	Other PI/r+2NRTI	2368	8.1	1.59(1.13 , 2.23)	3.9	1.51 (1.00, 2.30)
		1816	6.2	1.16( 0.82, 1.63)	3.5	1.01 (0.65 , 1.55)
Delivery year <sup>c</sup>	(per 1 year increase)	-	-	0.97 (0.92 , 1.02)	-	0.95 (0.88, 1.02)
	2007-2009	1996	7.5	-	4.1	-
	2010-2012	2293	6.4	-	3.8	-
	2013-2015	1784	5.9	-	3.4	-
Maternal age at delivery	<28years	1459	6.4	1.00	3.4	1.00
	28-32years	1514	7.1	1.27( 0.90, 1.79)	3.8	1.13 ( 0.71, 1.81)
	32-36years	1618	6.2	1.19( 0.84,1.70)	3.1	0.99 ( 0.61, 1.60)
	>36years	1482	6.7	1.28(0.89 , 1.84)	4.8	1.60 ( 1.01, 2.54)
Region of origin	WEWC+EE	1147	7.7	1.17(0.76 , 1.81)	4.5	1.72 (0.94, 3.16)
	East-Africa	2618	5.8	0.93 (0.63 ,1.36)	4.3	1.42 (0.82, 2.46)
	West-Africa	1035	6.8	1.11 (0.72,1.71)	2.9	1.01 (0.52, 1.97)
	Mid/South-Africa	781	6.2	1.00	2.8	1.00
	Caribbean	130	13.1	2.21(1.12 ,4.35)	1.5	0.84 (0.19 , 3.74)
	Other	362	7.2	1.10 (0.61, 1.98)	2.8	0.93 (0.38, 2.30)
Parity	Primiparous	1784	6.5	1.00	4.4	1.00
	Multiparous	4161	6.7	1.24 (0.94, 1.63)	3.4	0.71 (0.51, 0.99)
History of IDU	No	5968	6.6	1.00	3.7	1.00
	Yes	105	8.6	1.13 (0.47, 2.70)	8.6	2.39 (1.03, 5.55)
ART at conception	No	2983	7.2	1.00	3.3	1.00
	Yes	3090	6.0	1.02 (0.76, 1.36)	4.2	1.90 (1.30, 2.78)
First antenatal CD4 (cells/mm <sup>3</sup> )	>350	3272	6.1	1.00	3.4	1.00
	≤350	1505	7.1	1.15(0.89, 1.48)	4.4	1.50 (1.08,2.09)

IDU=injectable drug use; WEWC+EE=Western Europe and other Westernized Countries + Eastern Europe; <sup>a</sup>odds of delivering moderate preterm rather than full term- OR all mutually adjusted; <sup>b</sup> odds of delivering very preterm rather than full term- aOR all mutually adjusted; <sup>c</sup>delivery year by triennial presented only for the purpose of displaying PTD proportion changing overtime.

**SDC Table 2a Factors associated with pre-term deliveries in women on ART at conception stratified by baseline CD4 count**

ART at conception (n=2385)*		CD4≤350cells/μl			CD4>350cells/μl		
		N	%PTD	aOR*(95%CI)	N	%PTD	aOR**(95%CI)
		504	13.7		1881	8.8	
Regimen in pregnancy	NNRTI+2NRTI	263	10.3	1.00	973	8.2	1.00
	LPV/r+2NRTI	90	21.1	2.01(1.03, 3.91)	338	12.1	1.64(1.08, 2.47)
	Other PI/r+2NRTI	151	15.2	2.05(1.07, 3.89)	570	7.9	0.98(0.66, 1.46)
Calendar year***	2007-2009	152	20.4	-	335	7.8	-
	2010-2012	200	12.5	-	754	10.0	-
	2013-2015	152	8.6	-	732	8.2	-
	per 1 year increase	-	-	0.84(0.74, 0.95)	-	-	0.99(0.92, 1.07)
Maternal age	<28years	87	12.6	1.00	270	6.3	1.00
	28-32years	121	15.7	1.42(0.63, 3.22)	422	10.4	1.69(0.94, 3.05)
	32-36years	142	12.0	1.00(0.43, 2.33)	582	7.6	1.11(0.61, 2.01)
	>36years	154	14.3	1.22(0.54, 2.76)	607	10.1	1.64(0.92, 2.90)
Parity	Primiparous	144	11.8	1.00	414	8.9	1.00
	Multiparous	352	14.5	1.29(0.70,2.38)	1387	8.8	0.97(0.65,1.43)
Country of origin	WEWC+EE	59	17.0	1.62( 0.57, 4.58)	310	9.0	1.28(0.68, 2.43)
	East-Africa	243	14.4	1.29(0.56, 3.00)	908	9.8	1.29( 0.75, 2.23)
	West-Africa	99	12.1	1.26 (0.47, 3.35)	266	6.4	0.91(0.45, 1.82)
	Mid/South-Africa	74	12.2	1.00	239	7.1	1.00
	Caribbean	9	11.1	1.17(0.13, 10.92)	40	15.0	2.33 (0.85, 6.41)
	Other	20	10.0	1.09(0.20, 5.84)	118	7.6	0.94 (0.39, 2.26)

\*Women with IDU history excluded; \*\*Odds ratios all mutually adjusted; \*\*\*delivery year by triennial presented only for the purpose of displaying PTD proportion changing overtime.

**SDC Table 2b Factors associated with pre-term deliveries in women not on ART at conception stratified by baseline CD4 count**

No ART at conception (n=2313)*		CD4≤350cells/μl			CD4>350cells/μl		
		N	%PTD	aOR*(95%CI)	N	%PTD	aOR**(95%CI)
		979	10.4		1334	10.0	
Regimen in pregnancy	NNRTI-+2NRTI	159	10.1	1.00	67	10.5	1.00
	LPV/r+2NRTI	535	11.0	1.08 (0.60, 1.95)	864	11.2	1.12(0.48, 2.60)
	Other PI/r+2NRTI	285	9.5	0.82(0.42, 1.63)	403	7.2	0.69(0.29, 1.67)
Calendar year***							
	2007-2009	450	10.2	-	559	10.9	-
	2010-2012	345	10.4	-	493	9.7	-
	2013-2015	184	10.9	-	282	8.5	-
	Per 1 year increase			1.01 (0.91, 1.12)			0.98(0.89, 1.07)
Maternal age							
	<28years	299	1.4	1.00	485	8.9	1.00
	28-32years	271	8.9	0.78(0.43, 1.39)	347	10.1	1.42(0.87, 2.33)
	32-36years	236	11.0	0.92(0.51, 1.67)	302	9.9	1.33(0.80, 2.24)
	>36years	173	12.1	1.06(0.57,1.98)	200	12.5	1.95(1.12, 3.38)
Parity							
	Primiparous	361	8.0	1.00	448	11.6	1.00
	Multiparous	612	11.6	1.51(0.93,2.43)	863	9.3	0.73(0.50,1.08)
Region of origin							
	WEWC+EE	143		0.70(0.31,1.59)	331	12.4	1.71(0.88, 3.35)
	East-Africa	408	10.5	0.85(0.45, 1.59)	509	8.1	0.94( 0.49 , 1.82)
	West-Africa	212	10.9	0.92 (0.46, 1.86)	234	9.8	1.28 (0.62 , 2.62)
	Mid/South-Africa	131	11.5	1.00	155	9.0	1.00
	Caribbean	19	15.8	1.18(0.30, 4.62)	35	14.3	2.02 (0.66 , 6.16)
	Other	66	9.1	0.79(0.29, 2.16)	70	12.9	1.63(0.65 , 4.05)

\*Women with IDU history excluded; \*\*Odds ratios all mutually adjusted;\*\*\* delivery year by triennial presented only for the purpose of display PTD proportion changing overtime.

SDC Table 3 Pregnancies and PTD rate by the most frequent (<5%, n=3712) drug combinations sorted by NRTI backbone

NRTIs	Third drug	Class	All		NOT at conception				At conception			
			N	%PTD	CD4<=350		CD4>350		CD4<=350		CD4>350	
					N	%PTD	N	%PTD	N	%PTD	N	%PTD
			3712		785	11.3	954	10.7*	392	13.3	1467	8.7
3TC+ABC	NVP	NNRTI	288	8.7	13	15.4	<b>7*</b>	<b>28.6</b>	52	9.6	216	7.4
3TC+ZDV	LPV/r	PI	1325	11.1	445	11.0	752	11.3	24	20.8	104	7.7
3TC+ZDV	NVP	NNRTI	273	9.9	84	10.7	<b>17*</b>	<b>0.0</b>	47	14.9	125	8.8
TDF+FTC	ATV/r	PI	535	7.7	104	10.6	124	6.5	60	16.7	247	4.9
TDF+FTC	EFV	NNRTI	495	8.9	32	6.3	26	7.7	85	9.4	352	9.1
TDF+FTC	LPV/r	PI	283	14.8	47	12.8	80	12.5	33	21.2	123	15.5
TDF+FTC	DRV/r	PI	267	13.9	38	21.1	56	10.7	39	12.8	134	13.4
TDF+FTC	NVP	NNRTI	246	7.7	22	9.1	<b>6*</b>	<b>16.7</b>	52	9.6	166	6.6

3TC=Lamivudine; ZDV=Zidovudine; FTC=Emtricitabine; TDF=Tenofovir; ABC=Abacavir; LPV= Lopinavir; ATV=Atazanavir; EFV= Efavirenz; NVP=Nevirapine; DRV=Darunavir; /r=Ritonavir boosted; \*excluded from analysis by drug combination.

**SDC Table 4 Summary of sensitivity analyses (all models adjusted for maternal age, year of delivery, parity, maternal region and history of IDU excluded)**

<b><u>No ART at conception</u></b>	<b>Main model</b>	<b>Sensitivity model: ART starting &lt;28gw *</b>
CD4≤350cells/μl	N=979	N=962
	adjOR	adjOR
NNRTI+2NRTI	1.00	1.00
LPV/r+2NRTI	1.08 (0.60, 1.95)	1.04 (0.57, 1.89)
Other PI/r+2NRTI	0.82 (0.42, 1.63)	0.81 (0.41, 1.60)
CD4>350cells/μl	N=1334	N=1321
	adjOR	adjOR
NNRTI+2NRTI	1.00	1.00
LPV/r+2NRTI	1.12 (0.48, 2.60)	1.05 (0.45, 2.44)
Other PI/r+2NRTI	0.69 (0.29, 1.67)	0.67 (0.27, 1.62)

\*of the 91 pregnancies starting ART≥28GW 30 did not have CD4 count